Describing SMA Progression Over Time

Now Viewing

EP: 1.Describing SMA Progression Over Time

EP: 2.Unmet Needs of Older Patients Living With SMA

EP: 3.Examining the Importance of Early Treatment for SMA

EP: 4.Key Functional Milestones Affected by Disease Progression

EP: 5.The Importance of Supportive Care for Patients Living With SMA

EP: 6.Introduction to Therapies Used to Treat SMA

EP: 7.Splicing Modifiers and Gene Therapy for SMA

EP: 8.Key Clinical Considerations for the Management of SMA

EP: 9.Assessing Different Factors When Selecting a Treatment

EP: 10.Evaluating the Potential of Intrathecal Gene Therapy

EP: 11.Other Investigational Treatment Options for SMA

EP: 12.Insurance Considerations for SMA Therapies

EP: 13.Optimizing Multidisciplinary Care Approaches for the Future of SMA Management

EP: 14.Final Panel Thoughts on the Management of SMA

Clinical Brief: Treatment Approaches for SMA in Older Patients

Main Discussion Topics

• Introduction to SMA and the expert panel of specialists from neurology, pediatrics, and physical therapy
• Discussion of SMA progression over time, particularly focusing on functional decline in motor neurons and muscle function
• Evolution of SMA classification from traditional types (1 to 4) to more functional categories (nonsitters, sitters, walkers) due to treatment advancements
• The importance of SMN2 copy numbers in determining disease severity and potential functional outcomes

Key Points for Physicians

• SMA is now considered a life span disease with an extended adult phase, especially with newer interventions.
• For older patients, treatment goals focus on slowing functional decline rather than achieving developmental milestones.
• SMN2 copy numbers remain important predictors of maximum function, even with disease-modifying therapies.
• Classification has evolved from types 1 to 4 to functional categories (nonsitters, sitters, walkers) that better reflect treatment outcomes.

Notable Insights

The panel emphasized that disease phenotype is determined by inherent disease characteristics and secondary atrophy from disuse, creating a combined progression pattern that affects treatment approaches.

Clinical Significance

Understanding SMA as a life span condition requiring individualized care based on functional status and SMN2 copy numbers is essential for establishing realistic treatment expectations and goals in older patients.